Last 12 months
Inside the activity.
3 purchase rows · 13 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 2 | 3 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 2 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 06, 2021 Filed Dec 8, 2021 16:04 UTC |
Brake Rachael LouiseChief Scientific Officer
|
GrantStock Option(right to buy) · Derivative | 500,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001209191-21-068508 · doc4.xml · derivative · entry 1 Brake Rachael Louise · CIK 0001898023 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-12-06 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on December 6, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on January 6, 2023. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on December 6, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on January 6, 2023. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 20:43 UTC |
Jenkins John KennethDirector
|
GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041462 · doc4.xml · derivative · entry 2 Jenkins John Kenneth · CIK 0001742557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 20:43 UTC |
Jenkins John KennethDirector
|
GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041462 · doc4.xml · derivative · entry 1 Jenkins John Kenneth · CIK 0001742557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 16:40 UTC |
CATLIN AVERY WDirector
|
GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041455 · doc4.xml · derivative · entry 2 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 16:40 UTC |
CATLIN AVERY WDirector
|
GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041455 · doc4.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 16:41 UTC |
HOLMER ALAN FDirector
|
GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041459 · doc4.xml · derivative · entry 2 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 16:41 UTC |
HOLMER ALAN FDirector
|
GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041459 · doc4.xml · derivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 20:45 UTC |
Salzmann PeterDirector
|
GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041467 · doc4.xml · derivative · entry 2 Salzmann Peter · CIK 0001796309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 20:45 UTC |
Salzmann PeterDirector
|
GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041467 · doc4.xml · derivative · entry 1 Salzmann Peter · CIK 0001796309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 20:42 UTC |
Jacques Rachelle SuzanneDirector
|
GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041461 · doc4.xml · derivative · entry 2 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 20:42 UTC |
Jacques Rachelle SuzanneDirector
|
GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041461 · doc4.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 16:26 UTC |
White BarbaraChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 307,300 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007727 · doc4.xml · derivative · entry 2 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,300 Underlying: Common Stock · 307,300 shares Expires 2031-02-02 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 16:26 UTC |
White BarbaraChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 307,300 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007727 · doc4.xml · derivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,300 Underlying: Common Stock · 307,300 shares Expires 2031-02-02 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:37 UTC |
Moran Sean F.Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 307,300 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007742 · doc4.xml · derivative · entry 2 Moran Sean F. · CIK 0001451495 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,300 Underlying: Common Stock · 307,300 shares Expires 2031-02-02 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022 Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:37 UTC |
Moran Sean F.Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 307,300 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007742 · doc4.xml · derivative · entry 1 Moran Sean F. · CIK 0001451495 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,300 Underlying: Common Stock · 307,300 shares Expires 2031-02-02 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:35 UTC |
Cohen YuvalDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 956,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007741 · doc4.xml · derivative · entry 2 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 956,500 Underlying: Common Stock · 956,500 shares Expires 2031-02-02 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022 Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:35 UTC |
Cohen YuvalDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 956,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007741 · doc4.xml · derivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 956,500 Underlying: Common Stock · 956,500 shares Expires 2031-02-02 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:31 UTC |
Millian Craig StuartChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 307,300 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007736 · doc4.xml · derivative · entry 2 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,300 Underlying: Common Stock · 307,300 shares Expires 2031-02-02 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022 Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:31 UTC |
Millian Craig StuartChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 307,300 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007736 · doc4.xml · derivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,300 Underlying: Common Stock · 307,300 shares Expires 2031-02-02 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:42 UTC |
Moran Sean F.Chief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 87,500 | $1.40 Strike: $1.40 | $122,500.00 |
DisclosureSEC source: 0001209191-20-064849 · doc4.xml · derivative · entry 6 Moran Sean F. · CIK 0001451495 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020 F2 · derivative.exercise_date: The option is currently fully vested. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:42 UTC |
Moran Sean F.Chief Financial Officer
|
SaleCommon Stock | 87,500 | $1.75 | $153,125.00 |
DisclosureSEC source: 0001209191-20-064849 · doc4.xml · nonDerivative · entry 4 Moran Sean F. · CIK 0001451495 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,610 F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020 F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020 Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:42 UTC |
Moran Sean F.Chief Financial Officer
|
Exercise / conversionCommon Stock | 87,500 | $1.40 | $122,500.00 |
DisclosureSEC source: 0001209191-20-064849 · doc4.xml · nonDerivative · entry 3 Moran Sean F. · CIK 0001451495 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 21:42 UTC |
Moran Sean F.Chief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 53,610 | $1.00 Strike: $1.00 | $53,610.00 |
DisclosureSEC source: 0001209191-20-064849 · doc4.xml · derivative · entry 5 Moran Sean F. · CIK 0001451495 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,610 Underlying: Common Stock · 53,610 shares Expires 2024-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020 F2 · derivative.exercise_date: The option is currently fully vested. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 21:42 UTC |
Moran Sean F.Chief Financial Officer
|
SaleCommon Stock | 53,610 | $1.40 | $75,054.00 |
DisclosureSEC source: 0001209191-20-064849 · doc4.xml · nonDerivative · entry 2 Moran Sean F. · CIK 0001451495 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,610 F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020 F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020 Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 21:42 UTC |
Moran Sean F.Chief Financial Officer
|
Exercise / conversionCommon Stock | 53,610 | $1.00 | $53,610.00 |
DisclosureSEC source: 0001209191-20-064849 · doc4.xml · nonDerivative · entry 1 Moran Sean F. · CIK 0001451495 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:44 UTC |
Moran Sean F.Chief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 36,923 | $0.17 Strike: $0.17 | $6,118.14 |
DisclosureSEC source: 0001209191-20-064437 · doc4.xml · derivative · entry 3 Moran Sean F. · CIK 0001451495 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,923 Underlying: Common Stock · 36,923 shares Expires 2024-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020 F3 · derivative.exercise_date: The option is currently fully vested. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:44 UTC |
Moran Sean F.Chief Financial Officer
|
SaleCommon Stock | 36,923 | $1.32 | $48,627.59 |
DisclosureSEC source: 0001209191-20-064437 · doc4.xml · nonDerivative · entry 2 Moran Sean F. · CIK 0001451495 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,610 F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020 F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on December 14, 2020 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.31 to $1.35 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:44 UTC |
Moran Sean F.Chief Financial Officer
|
Exercise / conversionCommon Stock | 36,923 | $0.17 | $6,118.14 |
DisclosureSEC source: 0001209191-20-064437 · doc4.xml · nonDerivative · entry 1 Moran Sean F. · CIK 0001451495 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2020 Filed Nov 12, 2020 15:28 UTC |
Cohen YuvalDirector · Chief Executive Officer
|
PurchaseCommon Stock | 4,240 | $1.21 | $5,126.16 |
DisclosureSEC source: 0001209191-20-057851 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,330 Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 12:34 UTC |
Golumbeski GeorgeDirector
|
GrantStock Option(right to buy) · Derivative | 81,000 | $0.00 Strike: $7.91 | $0.00 |
DisclosureSEC source: 0001493152-20-012802 · ownership.xml · derivative · entry 1 Golumbeski George · CIK 0001586660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2030-07-06 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 20, 2020 Filed May 22, 2020 19:00 UTC |
Jenkins John KennethDirector
|
GrantStock Option(right to buy) · Derivative | 40,500 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001209191-20-031660 · doc4.xml · derivative · entry 1 Jenkins John Kenneth · CIK 0001742557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 40,500 shares Expires 2030-05-20 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 20, 2020 Filed May 22, 2020 15:00 UTC |
Hochman David PDirector
|
GrantStock Option(right to buy) · Derivative | 40,500 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001209191-20-031663 · doc4.xml · derivative · entry 1 Hochman David P · CIK 0001292834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 40,500 shares Expires 2030-05-20 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 20, 2020 Filed May 22, 2020 15:00 UTC |
CATLIN AVERY WDirector
|
GrantStock Option(right to buy) · Derivative | 40,500 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001209191-20-031659 · doc4.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 40,500 shares Expires 2030-05-20 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 20, 2020 Filed May 22, 2020 15:00 UTC |
HOLMER ALAN FDirector
|
GrantStock Option(right to buy) · Derivative | 40,500 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001209191-20-031662 · doc4.xml · derivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 40,500 shares Expires 2030-05-20 F1 · deemedExecutionDate: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 20, 2020 Filed May 22, 2020 19:00 UTC |
Jacques Rachelle SuzanneDirector
|
GrantStock Option(right to buy) · Derivative | 40,500 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001209191-20-031661 · doc4.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 40,500 shares Expires 2030-05-20 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 20, 2020 Filed May 22, 2020 19:00 UTC |
Salzmann PeterDirector
|
GrantStock Option(right to buy) · Derivative | 40,500 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001209191-20-031658 · doc4.xml · derivative · entry 1 Salzmann Peter · CIK 0001796309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 40,500 shares Expires 2030-05-20 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| March 17, 2020 Filed Mar 17, 2020 17:14 UTC |
Cohen YuvalDirector · Chief Executive Officer
|
PurchaseCommon Stock | 4,300 | $3.49 | $15,007.00 |
DisclosureSEC source: 0001209191-20-019502 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,090 Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 10:37 UTC |
White BarbaraChief Medical Officer
|
PurchaseCommon Stock | 15,606 | $3.63 | $56,649.78 |
DisclosureSEC source: 0001209191-20-019914 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,217 Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 17:18 UTC |
Millian Craig StuartChief Commercial Officer
|
PurchaseCommon Stock | 2,000 | $4.25 | $8,500.00 |
DisclosureSEC source: 0001209191-20-019954 · doc4.xml · nonDerivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 15:21 UTC |
Discordia Robert PaulChief Operating Officer
|
PurchaseCommon Stock | 2,840 | $3.54 | $10,053.60 |
DisclosureSEC source: 0001209191-20-019931 · doc4.xml · nonDerivative · entry 1 Discordia Robert Paul · CIK 0001784644 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,490 Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 17:22 UTC |
White BarbaraChief Medical Officer
|
GrantStock Option(right to buy) · Derivative | 226,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001209191-20-017393 · doc4.xml · derivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,000 Underlying: Common Stock · 226,000 shares Expires 2030-03-06 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 6, 2021, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 6, 2021. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:18 UTC |
Moran Sean F.Chief Financial Officer
|
GrantStock Option(right to buy) · Derivative | 226,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001209191-20-017383 · doc4.xml · derivative · entry 1 Moran Sean F. · CIK 0001451495 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,000 Underlying: Common Stock · 226,000 shares Expires 2030-03-06 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 6, 2021, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 6, 2021. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:31 UTC |
Cohen YuvalDirector · Chief Executive Officer
|
GrantStock Option(right to buy) · Derivative | 639,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001209191-20-017413 · doc4.xml · derivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,000 Underlying: Common Stock · 639,000 shares Expires 2030-03-06 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 6, 2021, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 6, 2021. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:28 UTC |
Millian Craig StuartChief Commercial Officer
|
GrantStock Option(right to buy) · Derivative | 226,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001209191-20-017408 · doc4.xml · derivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,000 Underlying: Common Stock · 226,000 shares Expires 2030-03-06 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 6, 2021, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 6, 2021. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:24 UTC |
Discordia Robert PaulChief Operating Officer
|
GrantStock Option(right to buy) · Derivative | 226,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001209191-20-017400 · doc4.xml · derivative · entry 1 Discordia Robert Paul · CIK 0001784644 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,000 Underlying: Common Stock · 226,000 shares Expires 2030-03-06 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 6, 2021, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 6, 2021. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:06 UTC |
Salzmann PeterDirector
|
GrantStock Option(right to buy) · Derivative | 66,600 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001493152-20-003663 · ownership.xml · derivative · entry 1 Salzmann Peter · CIK 0001796309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,600 Underlying: Common Stock · 66,600 shares Expires 2030-03-06 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Incentive Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Incentive Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 18:02 UTC |
Cohen YuvalDirector · Chief Executive Officer
|
PurchaseCommon Stock | 1,430 | $4.26 | $6,091.80 |
DisclosureSEC source: 0001209191-19-055941 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,790 Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 10:00 UTC |
White BarbaraChief Medical Officer
|
PurchaseCommon Stock | 3,424 | $4.38 | $14,991.64 |
DisclosureSEC source: 0001209191-19-056260 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,611 Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 16:07 UTC |
Millian Craig StuartChief Commercial Officer
|
PurchaseCommon Stock | 1,000 | $4.38 | $4,380.00 |
DisclosureSEC source: 0001209191-19-055930 · doc4.xml · nonDerivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 14:57 UTC |
Discordia Robert PaulChief Operating Officer
|
PurchaseCommon Stock | 2,500 | $4.62 | $11,558.50 |
DisclosureSEC source: 0001209191-19-055918 · doc4.xml · nonDerivative · entry 1 Discordia Robert Paul · CIK 0001784644 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,650 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.